|Market Cap (Intraday)||3.68B|
|2yr Forward PE||N/A|
Arvinas, Inc. Stock, NASDAQ:ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.